2-Amino Pyrimidine Hydrochloride

Product Type : 2-amino Pyrimidine Hydrochloride
Physical State : Powder
Usage : Commercial
Purity : 98%
Packaging Type : HDPE

Further Pharmaceutical (www.further-pharm.com) is an innovation-driven and service-oriented biopharmaceutical company with global operations that develops and manufactures specialty and generic drugs, pharmaceutical intermediates and APIs. We remain focused on advancing innovative drug formulations and progressing therapeutic products to improve human health and quality of life while reducing the medical expenses. Our North America Office located at Toronto, Canada with following business endeavors: 1. Marketing and Distributing APIs and Pharmaceutical Intermediates in North America: We supply a broad portfolio of APIs and Pharmaceutical Intermediates, particularly for oncology drugs, small molecule kinase inhibitors, folic acid product lines and those intermediates with difficulties of mass production or in global shortage. Our R&D team provides high quality customized organic synthesis, analytical method development and validation, quality characterizations, pilot and large scale GMP manufacturing, and pre-formulation studies to meet FDA or other regulatory standards. 2. Regulatory Consulting Service (US, Canada, Europe): Our experienced North America team of scientists offer one-stop efficient service with opportunities for pharmaceutical companies from China and other regions to register their products with FDA, Health Canada or EMA in shortened time and lowered costs. Further Pharmaceutical Service includes regulatory consulting, CTA, IND or NDA/ANDA submission, and clinical development programs. 3. Partnership to China FDA registration, licensing and Marketing: Further Pharmaceutical seeks strategic partnership with international companies and facilitate registration/importation/licensing drug products and pharmaceutical technologies to China. With our success of R&D platforms and GMP manufacturing in China, we welcome all formats of collaborations including but not limit to full IP/Patent licensing, joint venture for manufacturing and marketing, royalty on sales of imported drug products, shares on suppling raw material. For any service related questions, please contact Dr. He at Toronto Office by +1 905-2469348 or email: [email protected] Further Pharmaceutical Co., Ltd. (Wuxi Headquarter) is located at Wuxi City, China by the beautiful Tai Lake Shore and registered in prestigious Wuxi (Huishan) Life Science & Technology Industrial Park. We were founded with mission to create highest quality of Research & Development, manufacturing and marketing chain for small molecule and biologics innovative and generic drugs as well as pharmaceutical intermediates and APIs with our own IP and innovative drug delivery/formulation technologies. Our R&D Center at Wuxi has over 20000 square feet state-of-the-art facilities consisting of Generic Drugs Bioequivalence Evaluation Platform, Medicinal Chemistry Platform, Impurities Directional Preparation Technology Platform, Innovative Formulation Platform, Analytical Technology Platform, as well as Clinical Research Platform. Further Pharmaceutical Corporate Value (3-I): Integrity, Innovation, Impassioned.

• BUSINESS TYPE Exporter, Manufacturer
• EMPLOYEE COUNT 100
• ESTABLISHMENT 2011
• ANNUAL TURNOVER Rs 100000 Lakhs
• WORKING DAYS Monday To Friday
• PAYMENT MODE Cash on Delivery (COD)